| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
A thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors. [PubChem] |
| Indication |
For the management of the manifestations of schizophrenia. |
| Pharmacology |
Zuclopenthixol is a thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors. |
| Toxicity |
Although there have not been any cases of overdosage reported, the symptoms are likely to be somnolence, coma, extrapyramidal symptoms, convulsions, hypotension, shock, or hyper- or hypothermia. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
The metabolism of zuclopenthixol is mainly by sulphoxidation, side chain N-dealkylation and glucuronic acid conjugation. The metabolites are devoid of pharmacological activity. |
| Half Life |
20 hours (range 12-28 hours) for the tablet form, 19 days for the depot form. |
| Protein Binding |
Approximately 98%. |
| References |
| • |
[Link]
|
| • |
Khalifa AE: Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms. Pharmacol Biochem Behav. 2003 Jul;75(4):755-62.
[Pubmed]
|
|
| External Links |
|